{"prompt": "['2016N277425_03', 'CONFIDENTIAL', '2018N377698_00', '201749', 'Table 2', 'Description of UMEC Inhalation Powder via ELLIPTA', 'Formulation', 'First strip', 'Umeclidinium bromide blended with lactose monohydrate and', 'magnesium stearate1', 'Dosage Form', 'ELLIPTA Inhaler with 30 doses (1 strip with 30 blisters)', 'Unit Dose Strengths', '62.5mcg', 'Physical description', 'Dry white powder', 'Route of Administration', 'Inhaled', '1.', 'Magnesium stearate 0.6% w/w of total drug product', 'Table 3', 'Description of Placebo Inhalation powder via ELLIPTA', 'Formulation', 'First strip', 'Second strip', 'Lactose monohydrate blended with', 'Lactose monohydrate blended with', 'magnesium stearate1', 'magnesium stearate\u00b2', 'Dosage Form', 'ELLIPTA Inhaler with 30 doses (2 strips with 30 blisters per strip)', 'Unit Dose Strengths', 'Not applicable', 'Not applicable', 'Physical description', 'Dry white powder', 'Dry white powder', 'Route of Administration', 'Inhaled', '1.', 'Magnesium stearate 0.6% w/w of total drug product', '2.', 'Magnesium stearate 1% w/w of total drug product', 'Table 4', 'Description of salmeterol Inhalation powder via DISKUS', 'Formulation', 'First strip', 'Salmeterol Xinafoate blended with lactose monohydrate', 'Dosage Form', 'Diskus Inhaler with 60 doses (1 strip with 60 blisters per strip)', 'Unit Dose Strengths', '50 mcg', 'Physical description', 'White powder', 'Route of Administration', 'Inhaled', 'Table 5', 'Description of Placebo inhalation powder via DISKUS', 'Formulation', 'Lactose monohydrate', 'Dosage Form', 'Diskus Inhaler with 60 doses (1 strip with 60 blisters per strip)', 'Unit Dose Strengths', 'Not Applicable', 'Physical description', 'White powder', 'Route of Administration', 'Inhaled', 'Albuterol/salbutamol via metered-dose-inhaler (MDI) will be issued for reversibility', 'testing at Visit 1. Albuterol/salbutamol MDI for as needed (prn) use will be issued', 'throughout the study. Albuterol/salbutamo will be sourced from local commercial stock', 'if appropriate.', '6.2.', 'Medical Devices', 'The eMDI devices are provided by GSK and are used in this study to electronically', 'record rescue medication usage. They have US FDA 510(K) clearance to market (Class', '37']['2016N277425_03', 'CONFIDENTIAL', '2018N377698_00', '201749', 'II device) and EU CE marketing (Class I device). Description of the eMDI and its use', 'will be provided in the SRM.', '6.3.', 'Treatment Assignment', 'Subjects who meet the randomization criteria will be assigned to one of the 3 study', 'treatments in accordance with the randomization schedule generated by Clinical', 'Statistics, prior to the start of the study, using validated internal software.', 'Once a randomization number is assigned to a subject, it cannot be reassigned to any', 'other subject in the study.', 'This study will utilize RAMOS NG, which will provide a means for central allocation of', 'drug. Each investigator will be supplied with sufficient supplies to conduct the trial.', 'Additional treatment packs will be supplied as needed to the sites. Details of how to use', 'the RAMOS NG to randomize subjects is provided in the SRM.', 'The duration of treatment for each subject is 24 weeks. On the morning of each clinic', 'study visit, subjects will refrain from taking their morning dose of study treatment until', 'instructed to do so by clinic personnel. On the other days during the treatment period', '(i.e. \"non-clinic days\"), subjects will be instructed to self-administer their study treatment', 'in the morning and evening. Subjects should enter the time they take their study treatment', 'in the eDiary.', 'Subjects will be randomly assigned to one of the blinded study treatment regimens in', 'equal proportion (ratio of 1:1:1):', 'UMEC/VI 62.5/25 mcg once daily via ELLIPTA + placebo twice daily via', 'DISKUS', 'UMEC 62.5 mcg once daily via ELLIPTA + placebo twice daily via DISKUS', 'Salmeterol 50 mcg twice daily via DISKUS + placebo once daily via ELLIPTA', 'The randomisation will be stratified based on long-acting bronchodilator usage during', 'the run-in (none or one long-acting bronchodilator per day).', 'Study treatment/investigational product will be dispensed at Visits 2, 3 and 4.', 'In order to ensure subjects have sufficient doses of study treatment, they must return to', 'clinic within 30 days from V2 and 60 days from V3 respectively (see Time and event', 'table Section 7.1).', 'Used study drug and rescue medication will be collected at Visits 3, 4 and 5 or at the', 'Early Withdrawal Visit.', '6.4.', 'Planned Dose Adjustments', 'No dose adjustment is allowed for this study', '38']\n\n###\n\n", "completion": "END"}